advertisement
11.4 Prostaglandins (23)
Showing records 1 to 23
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins45543 The Role of the Prostaglandin EP4 Receptor in the Regulation of Human Outflow Facility
Millard LH; Woodward DF; Stamer WD
Investigative Ophthalmology and Visual Science 2011; 52: 3506-3513
45563 Intracellular signaling in human iridial fibroblasts and iridial melanocytes in response to prostaglandins, endothelin, isoproterenol, and other pharmacological agents
Sharif NA; Crider JY
Current Eye Research 2011; 36: 310-320
45614 The relationship between corneal hysteresis and the magnitude of intraocular pressure reduction with topical prostaglandin therapy
Agarwal DR; Ehrlich JR; Shimmyo M; Radcliffe NM
British Journal of Ophthalmology 2011;
46278 Alterations in anterior chamber depth in primary open-angle glaucoma patients during latanoprost therapy
Cankaya AB; Teberik P; Acaroglu G
Acta Ophthalmologica 2011; 89: 274-277
46116 Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
Inoue K; Masumoto M; Wakakura M; Tomita G
Clinical Ophthalmology 2011; 5: 393-396
46034 Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys
Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie M
Journal of Glaucoma 2011;
45880 Bilateral upper eyelid retraction caused by topical bimatoprost therapy
Noma K; Kakizaki H
Ophthalmic Plastic and Reconstructive Surgery 2011;
45553 Human choroidal melanocyte signal transduction responses to various pharmacological agents: focus on endothelin receptors
Sharif NA; Crider JY
Current Eye Research 2011; 36: 462-468
45990 The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients
Sorkhabi R; Alipanahi R; Eftakhari-Milani A; Ghojazadeh L
Journal of Glaucoma 2011; 20: 240-243
46126 Clinical trial of the generic product UNILAT following its efficiency and safety in glaucoma and intraocular hypertension
Strmen P; Jancus V; Okkelova J; Tvrdonova M
Česka a Slovenska Oftalmologie 2010; 66: 258-261
45823 Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360(degrees) synechial angle-closure glaucoma: A preliminary study
Vyas P; Naik U; Gangaiah JB
Indian Journal of Ophthalmology 2011; 59: 13-16
45816 The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness
Zhong Y; Shen X; Yu J; Tan H; Cheng Y
Cornea 2011; 30: 861-864
45874 Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension
Pfeiffer N
Graefe's Archive for Clinical and Experimental Ophthalmology 2011; 249: 1065-1071
45676 Changes of the Retina and Intrinsic Survival Signals in a Rat Model of Glaucoma following Brinzolamide and Travoprost Treatments
Park HYL; Kim JH; Lee DE; Lee JH; Park CK
Ophthalmic Research 2011; 46: 208-217
45630 A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WKM; Prasanna G; Chiroli V
Experimental Eye Research 2011;
45627 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2(alpha) agonist, in preclinical models
Krauss AHP; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WKM; Carreiro ST; Ongini E
Experimental Eye Research 2011;
45628 Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D
Experimental Eye Research 2011;
45645 Efficacy and safety of topical travoprost with sofzia(registered trademark) preservative for Japanese glaucoma patients
Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata A
Hiroshima Journal of Medical Sciences 2010; 59: 71-75
45938 Effect of a single drop of Latanoprost ophthalmic gel on intra ocular pressure in the treatment of glaucoma
Kulkarni SV; Sandeep HN; Shankar MS; Ranjit Kumar P; Someshwara Rao B; Ramesh B; Ashok Kumar PA
International Journal of Pharmaceutical Sciences 2010; 2: 429-435
45504 Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system
Liang H; Pauly A; Riancho L; Baudouin C; Brignole-Baudouin F
British Journal of Ophthalmology 2011; 95: 869-875
45940 Formulation and evaluation of Latanoprost ophthalmic gels
Sandeep HN; Kulkarni SV; Vinod R; Shankar MS; Someshwara Rao B; Ashok Kumar P
Journal of Global Pharma Technology 2010; 2: 35-39
46123 Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: A Canadian population-based analysis
Iskedjian M; Covert DW; Walker JH
Patient 2011; 4: 133-141
45976 Efficiency of glaucoma drug regulation in 5 European countries: A 1995-2006 longitudinal prescription analysis
De Natale R; Le Pen C; Berdeaux G
Journal of Glaucoma 2011; 20: 234-239
